Solvonis Therapeutics: Streamlined, sharpened and set for growth
Last updated: 18:56 05 Nov 2026 AEDT, First published: 23:39 03 Feb 2024 AEDT
Snapshot
- Solvonis Therapeutics to target binge eating disorder and gambling addiction with ketamine treatment
- Solvonis Therapeutics: Clinical-phase innovator flies under the radar. But for how much longer?
About the company
Solvonis Therapeutics plc is a late clinical-stage biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system disorders.
Headquartered in London and listed on the Main Market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and proprietary discovery-stage compounds across addiction and psychiatry.
How it is doing
Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) announced it will target binge eating disorder and gambling disorder first after the US Patent and Trademark Office allowed its claims covering the use of ketamine to treat all behavioural addictions.
The claims cover dissociative doses of at least 50 mg, given by any route, with or without psychotherapy.
The application includes three forms of the drug: racemic ketamine, esketamine and arketamine.
Professor David Nutt, Solvonis chief scientific officer, said that addiction traps people in patterns they struggle to break and ketamine "may open a window to change those patterns".
Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) told investors it has moved closer to expanding its Phase 3 alcohol addiction trial into Europe after signing an agreement with Portugal's national addiction institute and a local clinical partner.
The memorandum of understanding with ICAD, which operates under Portugal's Ministry of Health, and Panegreen will explore adding Portuguese clinical sites to the 280-patient MORE-KARE trial of SVN-001, which combines ketamine with structured psychological therapy to treat severe alcohol use disorder.
Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) says new analysis of its ketamine-based alcohol treatment shows patients cut heavy drinking days by 67% compared with placebo, more than four months after their last dose.
The company says that puts SVN-001 ahead of naltrexone, sold as Vivitrol, and the GLP-1 drugs semaglutide and pemvidutide on the same measure.
Insight: Solvonis Therapeutics: Clinical-phase innovator flies under the radar. But...
As the dust settles on its successful takeover of Awakn Life Sciences, investors are starting to appreciate the potential of Solvonis Therapeutics PLC (LSE:SVNS).
Yet the current valuation of £22 million doesn’t tell the full story.